Market Minds Advisory
Veterinary Infectious Disease Diagnostics Market

Veterinary Infectious Disease Diagnostics Market: Veterinary Infectious Disease Diagnostics Market: The Result Arrives After The Decision

Around seven in ten cases are treated before any laboratory result exists, because a vet standing in front of a waiting owner cannot hold treatment for two days while a sample travels.

Lead Analyst

Published

August 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$2.4BMarket Size 2025
2036 FORECAST VALUE$5.8BBase Case , 2026 to 2036
CAGR 2026 TO 20368.4 %Bull 9.6% / Bear 7.2%
INCREMENTAL OPPORTUNITY$3.2BNet 10- year value creation
EXPANSION MULTIPLE2.24x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory.

Reference laboratories take about 2.4 days and are more accurate than anything in a clinic. Roughly 71% of cases are treated before that result arrives, which means the better test frequently loses the decision it was ordered to inform. Accuracy is not what decides these purchases.
East Asia holds 29% of value on the world's largest pig and poultry populations and the surveillance programmes that go with them, with Chinese testing at roughly 27% of global volume. Antimicrobial susceptibility and resistance testing grows at 12.6%, half again the market rate of 8.4%, as stewardship rules begin requiring a test before treatment rather than merely recommending one. Veterinary stewardship arrived later than the human equivalent and is moving considerably faster.
Concentration reaches 52% and one heading covers two unrelated businesses. Companion animal testing is owner-paid, individual and fast. Production animal surveillance is herd-level, government-tendered and slow, and a single disease incursion can lift demand for one test by 48 times within weeks. Capacity built for a surge strands afterwards, and capacity not built forfeits the contract entirely, which makes planning genuinely impossible for anybody. Blended reporting describes neither business.
Market Definition
The market covers diagnostic testing for infectious disease in animals, including bacterial infection diagnostics, viral infection diagnostics, parasitic and vector-borne diagnostics, notifiable and surveillance disease testing, antimicrobial susceptibility and resistance testing, and fungal and opportunistic infection diagnostics. Non-infectious veterinary diagnostics including clinical chemistry, haematology, genetic and parentage testing, imaging, and vaccines or therapeutics are excluded from scope.
Base Year Value
$2.4B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.4% base case. Bull 9.6%. Bear 7.2%.
Fastest Growth Segment
Antimicrobial Susceptibility and Resistance Testing: 12.6% CAGR
Fastest Growth Country
India: 10.5% CAGR
Fastest Growth Region
South Asia and Pacific: 10.6% CAGR
Largest Region
East Asia: 29% of 2025 global value
Market Leaders
IDEXX Laboratories, Zoetis, Thermo Fisher Scientific, Neogen, bioMérieux. Source: MMA Analysis based on disclosed veterinary diagnostics revenue, company annual reports 2025.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Veterinary Infectious Disease Diagnostics Market Forecast Scenarios

veterinary-infectious-disease-diagnostics-market-size-forecast-scenario-1787708567896
Growth from 2020 to 2025 ran at 7.0% and disease incursions distorted almost every year within it. African swine fever and highly pathogenic avian influenza drove enormous surveillance testing volumes that arrived suddenly and receded unevenly. In-clinic testing continued spreading through companion animal practice on speed rather than accuracy. Antimicrobial stewardship began moving from guidance toward requirement in several jurisdictions across the same period.
The 8.4% base case rests on three mechanisms. Stewardship rules keep converting susceptibility testing from a discretionary step into a compulsory one, which is a regulatory conversion rather than a clinical persuasion. In-clinic rapid testing keeps displacing reference laboratory work on turnaround wherever a treatment decision cannot wait. And Asian production animal surveillance keeps expanding as herd sizes and biosecurity requirements both grow together. None of the three depends on new test technology arriving.
The bull case at 9.6% assumes stewardship testing requirements extend across further species and jurisdictions, converting a large discretionary population into a mandated one. The bear case at 7.2% is a quiet period without major incursions, which would remove the surveillance surges that have lifted reported value repeatedly and leave underlying growth resting on companion animal practice alone.

Answers That Arrive Too Late

A reference laboratory produces a better answer and produces it about 2.4 days later. A veterinarian standing in a consulting room with a sick animal and an owner waiting cannot hold treatment for that long, which is why roughly 71% of cases are treated before any laboratory result exists at all. The result then confirms or contradicts a decision already made. Accuracy is not what decides these purchases.
FIVE-FIRM CONCENTRATION52%Share of category revenue held by leading diagnostics companies
IN-CLINIC TEST PRICE$32Typical practice price for a rapid in clinic infection test
TOP TESTING COUNTRYChina 27%Chinese share of global veterinary infectious disease test volume
OUTBREAK DEMAND MULTIPLE48 timesPeak testing demand against baseline during a disease incursion
REFERENCE LABORATORY TURNAROUND2.4 daysTime from sample despatch to result from a reference laboratory
TREATED BEFORE RESULT71%Cases treated before any laboratory result becomes available
Two unrelated businesses share this heading and it causes persistent confusion. Companion animal diagnostics is individual, owner-paid, performed in the clinic and judged on speed. Production animal diagnostics is herd-level, surveillance-driven, laboratory-based and frequently funded by government or by the processing company rather than the farmer. The economics, the regulation and the customer all differ, and a company organised for one serves the other poorly.
Outbreak demand is the operational problem nobody solves elegantly. A disease incursion can raise testing demand for a specific pathogen by roughly 48 times within weeks and let it collapse just as quickly afterwards. Capacity built for a surge strands when the surge ends. Capacity not built means missing the event entirely, and surveillance contracts go to whoever can deliver at that moment.
"The lab is right and the clinic is fast, and fast wins because the animal is already being treated. That has been true for twenty years and half this industry still sells accuracy."
Director, Animal Health Diagnostics Practice · MMA Veterinary Diagnostics Practice · August 2026

Market Trends

Stewardship Converts Susceptibility Testing Into A Requirement

Antimicrobial stewardship rules across several jurisdictions are moving from recommending a susceptibility test before treatment toward requiring one, which converts a discretionary purchase into a compulsory step in a single regulatory decision. Growth at 12.6% follows that conversion rather than any clinical persuasion campaign. Veterinary stewardship arrived later than the human equivalent and is moving faster, since the regulatory precedent already exists and the arguments have already been rehearsed elsewhere. Manufacturers who participate in that rulemaking early shape requirements around tests they can actually supply at scale. Persuasion never moved it.
Market Impact: Generates 27% of test volume

Speed Beats Accuracy Where Treatment Cannot Wait

Reference laboratories take roughly 2.4 days and are genuinely more accurate, while about 71% of cases are treated before any result arrives at all. A vet with an owner waiting makes the decision first and receives confirmation later, which means the more accurate test frequently loses the case it was ordered to inform. In-clinic testing wins on turnaround rather than performance, and manufacturers competing on analytical sensitivity are contesting a criterion nobody is actually applying. Turnaround decides whether a result influences anything at all, and half this industry still competes on the other criterion.
Market Impact: Surges to 48 times baseline

Market Opportunities and Growth Drivers

Asian Herd Scale Drives Surveillance Testing Volume

China holds the world's largest pig and poultry populations and the surveillance programmes attached to them generate roughly 27% of global veterinary infectious disease test volume on their own. African swine fever and avian influenza monitoring have institutionalised testing at a scale no other region approaches. India grows fastest of any country at 10.5% as poultry and dairy production intensify and formal disease monitoring extends beyond the largest commercial operations. Domestic manufacturers compete effectively on price in tendered surveillance work across the region. Scale here has no equivalent anywhere. Volume dominates globally.
Market Impact: Serves 2 unrelated customer types

Incursions Create Surges Nobody Can Plan Capacity Against

A disease incursion raises demand for a specific pathogen test by roughly 48 times within weeks and lets it fall away just as fast once containment succeeds or the season turns. Capacity built for the surge strands afterwards, and capacity not built means missing a government surveillance contract awarded to whoever can deliver at the moment it matters. Manufacturers managing that volatility through flexible manufacturing and contract capacity hold a real operational advantage. Flexible manufacturing and contracted reserve capacity are the only workable answer anybody has found. Nobody plans this well.
Market Impact: Tenders across 1 fixed budget

Market Restraints and Challenges

Two Businesses Share One Heading And One Organisation

Companion animal testing is individual, owner-paid, in-clinic and judged on speed, while production animal surveillance is herd-level, laboratory-based and funded by governments or processors rather than farmers. Root cause is that both concern infectious disease in animals and nothing else about them matches. The commercial impact is organisations optimised for neither, since the capabilities transfer poorly. Mitigation involves separating the commercial structures, which few companies in this market have actually done. Very few companies here have separated them at all. Capabilities transfer very poorly between them. Separation is the only fix.
Market Impact: Converts 1 discretionary test compulsory

Surveillance Tendering Prices Testing As A Commodity

Notifiable disease surveillance is compulsory, high volume and procured through government tender, which produces enormous unit numbers at prices that leave very little margin per test. Root cause is that a mandated programme has a fixed budget and many qualified suppliers. The commercial impact is a segment carrying most of the volume and comparatively little of the value. Mitigation runs through capacity reliability during surges, which tenders increasingly weigh alongside price. Tenders increasingly weigh surge delivery alongside price. Margin per test remains negligible regardless. Reliability now matters too. Delivery beats price sometimes.
Market Impact: Decides before 2.4 day results
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows disease target: which class of pathogen or which surveillance obligation the test addresses, rather than the technology platform performing it or where the sample is analysed. Six targets cover the market without overlap. Test format and species are treated as separate commercial dimensions throughout this report. Test format cuts across every disease target here.
veterinary-infectious-disease-diagnostics-market-market-share-analysis-1787708568195

Antimicrobial Susceptibility and Resistance Testing

Stewardship rules across several jurisdictions are shifting from recommending a susceptibility test before antibiotic treatment toward requiring one, which converts a discretionary purchase into a compulsory step through a single regulatory decision rather than through any clinical argument. Growth at 12.6%, half again the market rate of 8.4%, follows that conversion directly. Veterinary stewardship arrived later than the human equivalent and is moving considerably faster, because the regulatory precedent already exists and the arguments have been rehearsed. Manufacturers participating in rulemaking early shape requirements around what they can actually supply. Regulation rather than clinical argument is what moves this volume, which is uncomfortable for commercial teams built around detailing veterinarians.
CAGR 12.6%

Viral Infection Diagnostics

Viral testing carries both halves of this market at once, covering companion animal respiratory and enteric disease in the clinic and production animal incursion surveillance in reference laboratories. Growth at 9.6% therefore reflects two quite different demand patterns arriving under one label. African swine fever and avian influenza monitoring have institutionalised production testing at very large scale, while companion animal viral panels compete on turnaround in practices where treatment begins before any result is available. One label therefore covers a government surveillance programme and a consulting room decision, which is why blended segment reporting describes neither of them accurately at all. Two demand patterns arrive together. Reporting them together helps nobody.
CAGR 9.6%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Geography follows herd scale for production testing and companion animal spending for clinic testing, which pull in different directions. East Asia leads on surveillance volume, North America on clinic value, and India grows fastest. Stewardship rulemaking varies enormously between jurisdictions and drives conversion unevenly. Conversion is uneven.

North America

Companion animal in-clinic testing carries most regional value, supported by owner spending and by practices that have installed analysers and rapid test formats extensively. Reference laboratory networks are well developed and lose cases on turnaround rather than on quality. Production animal surveillance is organised and well funded, particularly around avian influenza and cattle disease programmes. Antimicrobial stewardship requirements are developing at both federal and state level and are expected to convert discretionary susceptibility testing into required testing progressively. Group practice consolidation is concentrating in-clinic testing purchasing decisions into central teams rather than leaving them with individual veterinarians. Reference laboratory networks lose cases on turnaround rather than on quality anywhere. Stewardship rules are developing.
Share: 25% | CAGR: 7.6% (2026 to 2036)

Western Europe

Antimicrobial stewardship in veterinary medicine is furthest advanced here, with several countries already requiring susceptibility testing before certain antibiotic use rather than merely recommending it. That regulatory conversion is what makes the region commercially interesting despite smaller herd numbers than Asia. Production animal surveillance is highly organised through national programmes. Companion animal in-clinic testing is well established and insurance penetration supports diagnostic spending more reliably than in most other regions. Regulatory conversion rather than herd scale is what makes this region commercially interesting, since susceptibility testing volume follows the rule directly. Insurance penetration supports companion animal diagnostic spending more reliably than in most other regions. Production surveillance is highly organised through well established national programmes.
Share: 21% | CAGR: 6.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
veterinary-infectious-disease-diagnostics-market-country-cagr-analysis-1787708568538

Selling Speed And Surge Capacity

Roughly 71% of cases are treated before results arrive, reference turnaround runs about 2.4 days, incursions lift demand 48 times, and stewardship is converting testing into a requirement. Four levers work on turnaround, surge capacity, regulatory conversion and commercial separation rather than on analytical performance. Analytical performance decides very little. Speed and capacity decide.

Compete On Turnaround Rather Than Analytical Sensitivity

About 71% of cases are treated before any laboratory result arrives, because a vet with an owner waiting cannot hold treatment for the 2.4 days a reference laboratory needs. The more accurate test therefore loses the decision it was ordered to inform. Manufacturers competing on analytical sensitivity are contesting a criterion nobody applies at the point of care, while turnaround decides whether a result influences treatment at all. Speed is the whole argument here. A better answer arriving after treatment has begun informs nothing at all, which is a point manufacturers keep declining to concede.
Market Impact: Beats the whole 2.4 day laboratory turnaround time

Build Surge Capacity Before The Next Incursion

A disease incursion lifts demand for a specific pathogen test by roughly 48 times within weeks and drops it just as fast afterwards, which makes fixed capacity investment genuinely difficult to justify. Government surveillance contracts nonetheless go to whoever can deliver volume at the moment it is required. Flexible manufacturing and contracted reserve capacity cost money in quiet periods and win the contracts that only exist during the loud ones. Tenders weigh delivery capability alongside price now, which rewards the reserve nobody wants to fund. Reserve capacity is genuinely expensive.
Market Impact: Meets the whole 48 times demand surge requirement

Work Stewardship Rulemaking Not Clinical Persuasion

Susceptibility testing growing at 12.6% is being converted from a discretionary step into a compulsory one by regulation rather than by any clinical argument that manufacturers have made successfully. Engaging with stewardship rulemaking reaches the decision that actually changes volume. Veterinary stewardship is moving faster than the human equivalent did because the precedent exists, and manufacturers who participate early shape requirements around tests they can actually supply. Rules move volume that persuasion never did. Manufacturers who participate early shape requirements around tests they can actually supply, which is a considerably better position than reacting later.
Market Impact: Converts the whole 12.6% of testing segment growth

Separate Companion And Production Commercial Structures

Companion animal testing is owner-paid, individual, in-clinic and judged on speed, while production surveillance is herd-level, tendered and funded by governments or processors, and 2 more different businesses would be difficult to construct deliberately. Capabilities transfer poorly between them and organisations running both from one structure serve neither well. Separation costs overhead and lets each be run by people who understand what actually decides its outcomes. Separation costs overhead and produces two organisations that each understand their own customer properly. Neither is served well today. Overhead is the price of competence in both.
Market Impact: Serves the 2 genuinely unrelated businesses properly apart

Who Controls the Margin Pool

Measured on disclosed veterinary diagnostics revenue, the five largest companies hold a CR5 of 52%, which reflects a market split between a concentrated companion animal analyser business and a fragmented production surveillance one. IDEXX holds the strongest companion animal in-clinic position built on installed analysers and consumables, Zoetis and Thermo Fisher span both halves, and Neogen and bioMérieux hold established production and food safety positions. The two halves barely overlap in capability or in customer at all.
Three contests define activity. Companion animal in-clinic testing competes on turnaround and on installed analyser bases that lock consumable supply. Reference laboratory work competes on breadth and accuracy while losing cases on speed. And surveillance tendering competes on price and on demonstrated capacity to deliver during a surge, which is a different qualification entirely. A company organised for one contest is rarely equipped for the others.

Pressure builds as stewardship rules convert discretionary testing into required testing across more jurisdictions. Rankings shift toward whoever holds surge capacity and stewardship engagement. Domestic Asian manufacturers are taking tendered surveillance volume at prices international suppliers cannot match anywhere. Price alone no longer wins.
veterinary-infectious-disease-diagnostics-market-company-positioning-matrix-1787708568950

Competitive Moat and Risk Dimensions

IDEXX LABORATORIES

Moat: Installed Analyser Consumable Lock

IDEXX places analysers into companion animal practices and supplies the consumables that run on them, which ties a practice to its test menu for the working life of the instrument. That installed base took decades to build and cannot be displaced by a better individual test. A practice already running the analyser buys whatever tests fit it.
IDEXX LABORATORIES

Risk: Production Surveillance Absence

The installed analyser model serves companion animal practice and does not translate into herd-level surveillance testing procured through government tender at commodity prices. Roughly 27% of global test volume sits in Chinese surveillance programmes alone. Strength in one half of this market provides no position at all in the other.
THERMO FISHER SCIENTIFIC

Moat: Surveillance Capacity And Breadth

Thermo Fisher supplies reagents, platforms and reference capability across production animal surveillance at a scale that lets it absorb incursion surges reaching roughly 48 times baseline demand. Government tenders increasingly weigh demonstrated surge delivery alongside price. Building comparable flexible capacity requires manufacturing investment that sits idle through quiet periods, which few competitors will fund.
THERMO FISHER SCIENTIFIC

Risk: Tendered Commodity Pricing

Surveillance testing is compulsory, high volume and procured against fixed government budgets with many qualified suppliers, which leaves very little margin per test however reliable the supply. Domestic Asian manufacturers compete effectively on price in exactly this work. Capacity reliability wins contracts without producing the pricing power that scale usually delivers.

Players Tracked

Prominent Players

IDEXX Laboratories
Zoetis
Thermo Fisher Scientific
Neogen
bioMérieux

Other Key Players

Heska
Virbac
Bio-Rad Laboratories
QIAGEN
Randox Laboratories
Innovative Diagnostics
Bionote
MEGACOR Diagnostik
Woodley Equipment
Boehringer Ingelheim
Elanco
Indical Bioscience
Gold Standard Diagnostics
Fujifilm VET Systems
Shenzhen Bioeasy

Recent Developments

FEBRUARY 2025

Stewardship rule requires susceptibility testing before certain antibiotic use

A national stewardship rule moved from recommending to requiring susceptibility testing before specified veterinary antibiotic use, a regulatory development rather than any corporate transaction. That converts a discretionary diagnostic purchase into a compulsory step through a single decision rather than through any clinical persuasion. Volume followed immediately.
Signal: Regulatory conversion changes testing volume faster than any clinical argument manufacturers have ever made. Rules move volume.
JUNE 2025

Incursion surveillance contract awarded on demonstrated surge capacity

A government surveillance contract following a disease incursion was awarded on demonstrated capacity to deliver testing volume immediately rather than on unit price alone, a procurement outcome rather than any corporate event. Demand for the relevant pathogen test had risen many times over within a matter of weeks.
Signal: Surge delivery capability wins surveillance contracts that only exist during the periods it is needed. Price alone loses now.
OCTOBER 2025

Practice network standardises on in-clinic testing over reference laboratory

A companion animal practice network moved a substantial share of infection testing from reference laboratory despatch to in-clinic rapid formats, a procurement and clinical workflow decision rather than any transaction. Treatment decisions were being made before laboratory results arrived in the great majority of cases anyway.
Signal: Turnaround rather than accuracy decides whether a test influences treatment in companion animal practice. Speed decides relevance.

What A Test Costs

Cost structure separates sharply between the two halves of this market. In-clinic rapid formats carry antibody or antigen reagent, cassette housing, packaging and quality release at 38 to 47% of a test selling near 32 dollars, with the analyser placed separately. Reference laboratory testing carries labour, instrument depreciation and sample logistics instead, where transport and handling frequently exceed the reagent cost per sample entirely.
The volatility that mattered was reagent and consumable supply during incursion surges. Demand for specific pathogen tests rising many times over within weeks strained reagent supply chains repeatedly, and Thermo Fisher and QIAGEN disclosures reference capacity pressure across those periods. Cold chain and logistics costs also rose through 2022, which IEA industrial energy price data records for refrigerated distribution operations. Reagent supply strained repeatedly during those surge periods.

Exposure divides by market half rather than by scale. Companion animal suppliers carry analyser placement cost recovered through consumable margin over years. Surveillance suppliers carry manufacturing capacity that must absorb surges reaching roughly 48 times baseline while sitting underused between them. Domestic Asian manufacturers hold cost positions in tendered surveillance work that international suppliers cannot approach on price at all.
veterinary-infectious-disease-diagnostics-market-cost-volatility-analysis-1787708569271

Hold flexible reserve capacity for incursion surges

Demand for a specific pathogen test can rise many times over within weeks of an incursion and fall away just as quickly once containment succeeds. Fixed capacity strands afterwards and absent capacity loses the contract entirely. Contracted flexible manufacturing costs money through quiet periods and wins the surveillance awards that only exist during the loud ones.

Recover analyser placement through consumable pricing

In-clinic analysers placed into practices are recovered through consumable supply across the instrument's working life rather than through equipment margin at the point of sale. Pricing the consumable correctly determines whether the placement pays for itself. Suppliers pricing equipment to recover cost win fewer placements and lose the consumable stream that follows each one.

Separate cost bases for clinic and surveillance work

In-clinic testing carries reagent and cassette manufacturing against consumer-facing pricing, while surveillance carries capacity and logistics against fixed tender budgets. Running both through one cost structure obscures which is actually earning anything. Separating them shows plainly where margin sits, which several companies in this market have never done properly. Blended reporting hides which half is actually profitable.

Portfolio Architecture for Margin Defence

Margin follows customer type far more than test complexity. Notifiable surveillance testing earns very little per unit against fixed tender budgets despite carrying enormous volume. Parasitic and vector-borne testing earns moderately across both halves. Bacterial and fungal diagnostics earn better in clinic formats. Viral panels earn well where in-clinic turnaround justifies pricing. Antimicrobial susceptibility testing earns best, because regulation is converting it from optional into required.
The tension is that volume and value sit in different halves of the same market. Surveillance carries the test numbers and almost none of the margin, while companion animal clinic testing carries the margin on a fraction of the volume. Companies reporting a single category figure obscure that completely, and several have built commercial organisations around a blended picture that describes neither business accurately at all.

High-value pools sit in three places. Antimicrobial susceptibility testing where stewardship rules are converting discretionary purchases into required ones. In-clinic rapid formats sold on turnaround into analyser bases that lock consumable supply. And demonstrated surge capacity, which wins surveillance contracts that price alone does not. All three sit outside the blended category figure that most companies still report.

Volume / Commodity-Adjacent

Notifiable disease surveillance testing procured through government tender against fixed programme budgets. The 9-point range is wide because domestic and international suppliers face entirely different cost positions on identical tendered surveillance work.
Gross Margin: 16-25%

Premium / Certified

Reference laboratory bacterial, parasitic and fungal diagnostics together with production animal testing outside mandated surveillance programmes. The 10-point spread separates laboratories with breadth and accreditation from those competing on price for routine sample volume.
Gross Margin: 42-52%

Sustainability / Regulatory / Next-Generation

In-clinic rapid infection formats and antimicrobial susceptibility testing supplied into analyser bases and regulatory requirements. The 22-point range is wide because consumable margins on placed analysers and susceptibility testing economics differ considerably.
Gross Margin: 56-78%
veterinary-infectious-disease-diagnostics-market-portfolio-architecture-1787708569633

High-value Sub-segments and Strategic Watch-out

Antimicrobial Susceptibility Testing

Highest margin and fastest growth at 12.6%, converted from a discretionary purchase into a required step by stewardship regulation rather than by any clinical argument. The risk is that rulemaking varies enormously between jurisdictions, so growth arrives unevenly and cannot be forecast from clinical need alone.
Gross Margin: 70-78%

In-Clinic Rapid Formats

Strong margins on consumables running through placed analysers, winning on turnaround where treatment begins before laboratory results arrive. The risk is that the position depends on the installed analyser base, and a practice that replaces its instrument replaces its whole test menu with it. Analysers decide it.
Gross Margin: 60-68%

Surveillance Test Volume

The volume core, carrying the largest test numbers globally at tendered prices that leave very little per unit. Suppliers hold it because surge delivery capability wins contracts and because presence in surveillance supports credibility across the whole production animal business. Credibility follows presence there. Nobody exits it.
Gross Margin: 17-23%

Incursion Demand Volatility

The strategic watch-out. Demand for a specific pathogen test can move 48 times within weeks and collapse just as fast, which makes capacity planning genuinely impossible. The risk is that fixed investment strands while absent capacity forfeits the contract entirely. Nobody plans it well. Planning stays impossible.
Gross Margin: 24-30%

Steady Clinics Volatile Herds

Two demand patterns coexist and behave nothing alike. Companion animal clinic testing is steady, tracking consultation volume and reflecting owner willingness to pay for an answer during the appointment. Production surveillance testing is mandated, tendered and violently volatile, moving many times over within weeks of an incursion and falling away afterwards. Forecasting one from the other produces nonsense, and blended category figures do exactly that.
Stickiness works differently in each half too. In-clinic testing is locked by the analyser installed in the practice, which ties the test menu to that instrument for its working life. Surveillance testing is locked by nothing except the current tender, which is rebid on schedule and awarded on price and demonstrated capacity. Reference laboratory relationships sit between the two, sticky through habit and turnaround rather than through anything contractual.

The decision maker could hardly differ more. A veterinarian in a consulting room chooses an in-clinic test on turnaround while an owner waits. A government procurement body awards surveillance testing on price and capacity across a national programme. A processor may specify testing as a supply condition. Companies organised for one of those buyers reach the others only by accident, and most are organised for one.
veterinary-infectious-disease-diagnostics-market-end-use-penetration-index-1787708569915

Where Speed And Capacity Decide

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / TURNAROUND COMPETITION PRIORITY

The accurate answer arrives after treatment starts

Reference laboratories produce a genuinely better result, and they produce it roughly 2.4 days later than the clinic does, while about 71% of cases are treated before any laboratory result exists at all. A veterinarian with a sick animal and a waiting owner simply cannot hold treatment while a sample travels somewhere else entirely. Manufacturers who compete on analytical sensitivity are therefore contesting a criterion that nobody in the room is applying at the moment the decision actually gets made.
02 / SURGE CAPACITY PREPARATION

Contracts exist only when demand explodes

A single disease incursion can lift demand for one specific pathogen test by roughly 48 times within a matter of weeks, and let it collapse just as quickly once containment succeeds or the season turns. Fixed capacity built for a surge strands afterwards, while capacity that was never built at all means forfeiting a government surveillance contract entirely. Flexible manufacturing and contracted reserve capacity cost real money through the quiet periods, and they win the awards during the loud ones.
03 / REGULATORY CONVERSION ENGAGEMENT

A rule changes volume faster than persuasion

Antimicrobial susceptibility testing growing at 12.6% annually is being converted from a purely discretionary clinical step into a compulsory one by stewardship regulation, rather than by any argument that manufacturers have successfully made to practising veterinarians over many years. Engaging directly with stewardship rulemaking therefore reaches the one decision that genuinely changes testing volume at all. Veterinary stewardship is now moving considerably faster than its human equivalent did, because the regulatory precedent already exists and the arguments have been rehearsed.
04 / BUSINESS MODEL SEPARATION

One heading, two entirely different companies

Companion animal testing is owner-paid, individual, performed inside the clinic and it is judged almost purely on speed, while production surveillance is herd-level, laboratory-based, tendered competitively and funded by governments or by processing companies instead. Two more genuinely different businesses would be very difficult to construct on purpose, and the capabilities involved transfer very poorly indeed between the two of them. Organisations that run both through one single commercial structure end up serving neither of the two particularly well at all.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Veterinary Infectious Disease Diagnostics Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Veterinary Infectious Disease Diagnostics Exposure Evaluation 2025-26
CLIENT PROFILE
A veterinary diagnostics company supplying both companion animal test formats and production animal surveillance testing across European and Asian markets, with reported diagnostics revenue of 210 million dollars (client-reported, unverified by MMA). Both businesses ran through a single commercial organisation. No surge capacity arrangements existed and stewardship rulemaking had never been engaged with anywhere. Margin by half had never been separated.
STRATEGIC CHALLENGE
Surveillance tender losses had increased while companion animal clinic sales grew more slowly than the market, and management could not identify a common cause. A manufacturing cost programme and a product range extension were being prepared. Neither addressed whether one organisation could serve two unrelated customers effectively at the same time.
MMA APPROACH
MMA separated revenue, cost and margin by market half, which the company had never distinguished internally, and modelled surveillance tender outcomes against capacity criteria. Eighteen expert interviews with practising veterinarians, government procurement officials and processor quality leads established how each buyer decides. The analysis treated organisational structure and surge capacity rather than product performance as the causes.
KEY FINDINGS
  1. Separating the two halves showed surveillance carrying most test volume and almost none of the margin, a distinction the blended reporting had entirely obscured from management.
  2. Recent surveillance tender losses had turned on demonstrated surge capacity rather than price, and the company held no flexible manufacturing arrangements of any kind.
  3. Veterinarians interviewed selected in-clinic tests on turnaround and had never considered analytical sensitivity, which the company's materials led with throughout. Nobody had asked them.
  4. Stewardship rulemaking in two served markets was advancing without any input from the company, while competitors had participated in consultation processes. Requirements were being shaped without them.
CLIENT PROFILE
A veterinary diagnostics company supplying both companion animal test formats and production animal surveillance testing across European and Asian markets, with reported diagnostics revenue of 210 million dollars (client-reported, unverified by MMA). Both businesses ran through a single commercial organisation. No surge capacity arrangements existed and stewardship rulemaking had never been engaged with anywhere. Margin by half had never been separated.
STRATEGIC CHALLENGE
Surveillance tender losses had increased while companion animal clinic sales grew more slowly than the market, and management could not identify a common cause. A manufacturing cost programme and a product range extension were being prepared. Neither addressed whether one organisation could serve two unrelated customers effectively at the same time.
MMA APPROACH
MMA separated revenue, cost and margin by market half, which the company had never distinguished internally, and modelled surveillance tender outcomes against capacity criteria. Eighteen expert interviews with practising veterinarians, government procurement officials and processor quality leads established how each buyer decides. The analysis treated organisational structure and surge capacity rather than product performance as the causes.
KEY FINDINGS
  1. Separating the two halves showed surveillance carrying most test volume and almost none of the margin, a distinction the blended reporting had entirely obscured from management.
  2. Recent surveillance tender losses had turned on demonstrated surge capacity rather than price, and the company held no flexible manufacturing arrangements of any kind.
  3. Veterinarians interviewed selected in-clinic tests on turnaround and had never considered analytical sensitivity, which the company's materials led with throughout. Nobody had asked them.
  4. Stewardship rulemaking in two served markets was advancing without any input from the company, while competitors had participated in consultation processes. Requirements were being shaped without them.
RECOMMENDED STRATEGY
Phase 1: Phase one: separate the companion animal and surveillance commercial organisations, staffing each with people who understand what decides its outcomes. Phase 2: Phase two: contract flexible reserve manufacturing capacity, since surveillance tenders now weigh surge delivery alongside price in awarding contracts. Reserve wins contracts. Phase 3: Phase three: engage stewardship rulemaking in served markets, since regulation converts testing volume faster than clinical persuasion ever has. Precedent already exists.
OUTCOME
The two commercial organisations were separated and margin visibility by market half improved immediately for the first time. Flexible capacity was contracted and the company was shortlisted for two surveillance tenders it would previously have failed on capacity grounds (client-reported, unverified by MMA). Stewardship engagement began in both served markets ahead of the next consultation round.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Veterinary Infectious Disease Diagnostics Market?

The market was worth 2.4 billion dollars in 2025, covering bacterial, viral, parasitic, surveillance, susceptibility and fungal infection testing. It reaches 2.60 billion dollars in 2026.

How large will the Veterinary Infectious Disease Diagnostics Market be by 2036?

MMA forecasts 5.83 billion dollars by 2036, an increase of 3.23 billion dollars over the 2026 base. That represents an expansion multiple of 2.24 times across the forecast period.

What is the CAGR for the Veterinary Infectious Disease Diagnostics Market 2026 to 2036?

The base case compounds at 8.4% annually. The bull case reaches 9.6% if stewardship testing requirements extend further, while the bear case sits at 7.2% on a quiet period without major incursions.

Which segment is growing fastest?

Antimicrobial susceptibility and resistance testing, at 12.6%, half again the market rate of 8.4%. Stewardship rules are converting it from a discretionary step into a compulsory one.

Who are the major companies in the Veterinary Infectious Disease Diagnostics Market?

IDEXX Laboratories, Zoetis, Thermo Fisher Scientific, Neogen and bioMérieux lead on disclosed veterinary diagnostics revenue. Heska, Innovative Diagnostics and Bionote hold notable format or regional positions.

Which country is growing fastest?

India at 10.5%, as poultry and dairy production intensify and formal monitoring extends beyond the largest operations. China generates roughly 27% of global veterinary test volume.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Disease Target

  • Bacterial Infection Diagnostics
  • Viral Infection Diagnostics
  • Parasitic and Vector-Borne Diagnostics
  • Notifiable and Surveillance Disease Testing
  • Antimicrobial Susceptibility and Resistance Testing
  • Fungal and Opportunistic Infection Diagnostics

By End-Use Setting

  • Companion Animal Practices
  • Veterinary Reference Laboratories
  • Government Surveillance Laboratories
  • Production Animal Veterinary Services
  • Food Processor Quality Programmes
  • Veterinary Teaching and Research Institutions

By Commercial Dimension

  • In-Clinic Analyser Consumable Supply
  • Reference Laboratory Service
  • Government Surveillance Tender Supply
  • Processor Specified Testing Supply
  • Export Certification Testing
  • Research and Institutional Supply

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
Scope covers diagnostic testing for infectious disease in companion, production, equine and exotic animals, spanning bacterial infection diagnostics, viral infection diagnostics, parasitic and vector-borne diagnostics, notifiable and surveillance disease testing, antimicrobial susceptibility and resistance testing, and fungal and opportunistic infection diagnostics. Non-infectious veterinary diagnostics including clinical chemistry, haematology and endocrinology, genetic, parentage and breed testing, veterinary imaging of every kind, vaccines, therapeutics and biosecurity products, and human infectious disease testing are excluded from the market size and all derived figures. Molecular platform technology is analysed in a separate MMA report.
Quantitative Units
USD billions (current prices); tests performed; price per test; turnaround time in days; surveillance programme coverage
Segmentation Dimensions
By Disease Target; By End-Use Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
China, USA, India, Germany, Brazil, Japan, France, UK, Spain, Vietnam, Netherlands, Poland, Mexico, Australia, Thailand
Key Companies Profiled
IDEXX Laboratories, Zoetis, Thermo Fisher Scientific, Neogen, bioMérieux, Heska, Virbac, Bio-Rad Laboratories, QIAGEN, Randox Laboratories, Innovative Diagnostics, Bionote, MEGACOR Diagnostik, Woodley Equipment, Boehringer Ingelheim, Elanco, Indical Bioscience, Gold Standard Diagnostics, Fujifilm VET Systems, Shenzhen Bioeasy
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-132
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Veterinary Infectious Disease Diagnostics Market Report (2026 to 2036).

The full report runs to 172 pages and covers all six disease target segments, seven regions and 20 profiled companies in detail. It includes the complete segment CAGR set, regional surveillance programme and stewardship comparison, and separated economics for companion animal and production animal testing. Company profiles carry evaluation on disclosed veterinary diagnostics revenue, with moat and risk assessment for the top five companies. The competitive section extends to 15 tracked regulatory, procurement and corporate developments across 2024 and 2025. Primary research inputs include a quantitative survey of 3,800 respondents and 47 expert interviews conducted in Q4 2025.
Six disease target segments with individual CAGR forecasts
Seven regional markets with surveillance and stewardship comparison
Twenty company profiles on consistent diagnostics revenue evaluation basis
Fifteen tracked regulatory and procurement developments with commercial interpretation
Separated economics for companion animal and production animal testing
Incursion demand volatility modelled against manufacturing capacity scenarios

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts